Global Human Insulin Market Size, Share, Value, And Competitive Landscape 2021-2026

Report Description
Introduction
Diabetes is a chronic disease caused due to insufficient production or inappropriate use of insulin in the body. It is a collection of diseases characterized by elevated blood glucose level. It is mainly of two types –Type 1 and Type 2 diabetes. Type 1 is caused due to lack of insulin, whereas, type 2 diabetes is caused due to futile use of insulin. According to World Health Organization (WHO) in 2012, globally 1.5 million people died due to diabetes. In addition, according to American Diabetes Association (ADA) in 2012, 29.1million Americans were suffering from the disease. Human insulin is synthetic insulin which is developed in laboratories by growing insulin protein with the help of E coli bacteria.

GET FREE SAMPLE REPORT :https://www.wiseguyreports.com/sample-request/740956-global-human-insulin-market-development-and-demand-research-report-forecast-to-2020

The global human insulin market is growing moderately due to increase in prevalence of diabetic population, rise in geriatric population, rising awareness of diabetes and rising prevalence of obesity. However, strict regulatory requirements for approval of insulin and high cost of analog are inhibiting the growth of the global human insulin market.
The global human insulin market was valued at $ 26 billion and is expected to grow at a CAGR of 12.5% during the forecast period.
On the basis of types, modern human insulin is by far the fastest growing segment of human insulin market and it is expected to reach $42 billion by 2020.

SHARE YOUR QUERIES :https://www.wiseguyreports.com/enquiry/740956-global-human-insulin-market-development-and-demand-research-report-forecast-to-2020

Based on type of brands, Lantus is long acting human insulin analog and it is available in more than 120 countries. Among all the brands, Lantus commands the largest share in the human insulin market. Apidra is rapid acting human insulin analog. In addition, Apidra and Levemir are the fastest growing brand in the human insulin market. Moreover, there are various drugs in pipeline, which would have positive impact on the growth of the market in coming years.
Geographically, North America is one of the major revenue generator as well as producer of human insulin. Increasing prevalence of diabetes and increasing R&D investment for more effective insulin is boosting the growth of human insulin market in North America.

REPORT DETAILS :https://www.wiseguyreports.com/reports/740956-global-human-insulin-market-development-and-demand-research-report-forecast-to-2020

Key Players
The leading market players in the global human insulin market include; Biocon Ltd. (India), Merck & Co (U.S.), Pfizer, Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), GlaxoSmithKline Plc (U.K.), Novo Nordisk A/S (Denmark), Eli Lilly and Company (U.S.), Sanofi (France), Tonghua Dongbao Pharmaceuticals Co., Ltd. (China), ADOCIA (France), and others.
Study Objectives of Human Insulin Market Development and Demand Forecast to 2020
Ø To provide insights about factors, influencing and affecting the market growth.
Ø To provide historical and forecast revenue of the market segments and sub-segments with respect to regional markets and their countries.
Ø To provide historical and forecast revenue of the market segments based on type, and brands, for global human insulin market.
Ø To provide strategic profiling of key players in the market, comprehensively analyzing their market share, core competencies, and drawing a competitive landscape for the market.
Ø To provide economic factors that influences the global human insulin market.

Target Audience
• Pharmaceutical companies
• Medical devices companies
• Urologist
• Research Laboratories
• Hospitals & Clinics
• Component and Raw Material Suppliers
• Service Suppliers
• Potential Investors
• Key executive (CEO and COO) and strategy growth manager

Key Findings
• The global market for human insulin is expected to grow at a CAGR of 12.5% during the period 2016 to 2020 to reach $48 billion by 2020.
• The Asian human insulin market is expected to grow rapidly during 2016 to 2020; whereas, North America will remain the largest market by end of the forecast period.
• By types, modern human insulin segment is expected to witness highest CAGR of 12.7% during the period 2016 to 2020.
• Pfizer, Inc., Novo Nordisk, Eli Lily and Company, Sanofi, GlaxoSmithKline and Merck & Co. are so far the leading market players for human insulin market globally

Regional and Country Analysis of Human Insulin Market Development and Demand Forecast to 2020
As per the MRFR analysis, the Asia human insulin market is poised to reach $XX billion by 2020, to grow at a CAGR of around 12.5% during the forecasted period. European market was valued at $ XX million in 2015, and expected to reach at $ 14 billion by 2020. North America continues to be the leading region and valued at $11 billion in 2015.
The reports also cover country level analysis:
• North America
o US
o Canada
• Europe
o Germany
o U.K.
o Italy
o Spain
o France
o Rest of Western Europe
o Eastern Europe
• Asia-Pacific
o Japan
o China
o India
o Republic of Korea
o Rest of Asia-Pacific

Table of Content

CHAPTER 1.RESEARCH SCOPE AND METHODOLOGY 16
1.1 MARKET DEFINITION 16
1.2 MARKET BREAKDOWN BY DIFFERENT CATEGORIES 16
1.3 MARKET BREAKDOWN BY GEOGRAPHY 17
1.4 RESEARCH METHODOLOGY AND SOURCES 17
CHAPTER 2.EXECUTIVE SUMMARY 19
2.1 KEY FINDINGS 19
2.2 RESEARCH SUMMARY 19
CHAPTER 3.MARKET OUTLOOK 21
3.1 INTRODUCTION 21
3.2 TRENDS IN THE MARKET 23
3.2.1RISING USAGE OF INSULIN PEN FOR THE ADMINISTRATION OF HUMAN INSULIN 23
3.3 OPPORTUNITIES IN THE MARKET 23
3.3.1GROWING DEMAND OF BIOSIMILAR DRUGS DUE TO ITS COST EFFECTIVENESS 23
3.4 FACTORS DRIVING THE MARKET AND ITS IMPACT ON MARKET FORECAST 24
3.4.1RISING AGING POPULATION 24
3.4.2INCREASING DIABETIC POPULATION 25
3.4.3RISING PREVALENCE OF OBESITY 25
3.4.4 TECHNOLOGICAL ADVANCEMENT IN DRUG DELIVERY DEVICES 27
3.4.5INCREASING AWARENESS ABOUT DIABETIC CARE 27
3.4.6IMPACT ANALYSIS OF DRIVERS ON MARKET FORECAST 27
3.5 FACTORS HINDERING THE MARKET AND ITS IMPACT ON MARKET FORECAST 28
3.5.1HIGH INSULIN ANALOGUE COST 28
3.5.2 STRICT REGULATORY REQUIREMENTS FOR APPROVAL OF HUMAN INSULIN 28
3.5.3IMPACT ANALYSIS OF RESTRAINTS ON MARKET FORECAST 29
CHAPTER 4.GLOBAL MARKET SIZE AND FORECASTS (2011 – 2020) 30
4.1 GLOBAL MARKET BREAKDOWN BY TYPE 30
4.2 GLOBAL TRADITION HUMAN INSULIN MARKET BREAKDOWN BY TYPE 31
4.3 GLOBAL MODERN HUMAN INSULIN MARKET BREAKDOWN BY TYPE 32
4.4 GLOBAL MARKET BREAKDOWN BY REGION 33
CHAPTER 5.GLOBAL MARKET BREAKDOWN BY TYPE 35
5.1 TRADITIONAL HUMAN INSULIN MARKET BREAKDOWN BY REGION 35
5.2 MODERN HUMAN INSULIN MARKET BREAKDOWN BY REGION 36
CHAPTER 6.GLOBAL TRADITIONAL HUMAN INSULIN MARKET BREAKDOWN
BY TYPE 38
6.1 GLOBAL SHORT ACTING HUMAN INSULIN MARKET BREAKDOWN BY REGION 38
6.2 GLOBAL INTERMEDIATE ACTING HUMAN INSULIN MARKET BREAKDOWN BY REGION 39
6.3 GLOBAL PREMIXED HUMAN INSULIN MARKET BREAKDOWN BY REGION 40
CHAPTER 7. GLOBAL MODERN HUMAN INSULIN MARKET BREAKDOWN BY TYPE 42
7.1 GLOBAL LONG ACTING HUMAN INSULIN MARKET BREAKDOWN BY REGION 42
7.2 GLOBAL RAPID ACTING HUMAN INSULIN MARKET BREAKDOWN BY REGION 43
7.3 GLOBAL PREMIXED HUMAN INSULIN MARKET BREAKDOWN BY REGION 45
CHAPTER 8.GLOBAL MARKET BREAKDOWN BY BRAND 47
CHAPTER 9.GLOBAL MARKET BREAKDOWN BY REGION 50
9.1 NORTH AMERICA MARKET BREAKDOWN BY COUNTRY, TECHNOLOGY, END USERS AND APPLICATIONS 50
9.1.1 THE U.S. MARKET BREAKDOWN BY TYPE OF HUMAN INSULIN, BY TYPE OF TRADITIONAL HUMAN INSULIN, AND BY TYPE OF MODERN HUMAN INSULIN 54
9.1.2 CANADA MARKET BREAKDOWN BY TYPE OF HUMAN INSULIN, BY TYPE OF TRADITIONAL HUMAN INSULIN, AND BY TYPE OF MODERN HUMAN INSULIN 58
9.2 EUROPE MARKET BREAKDOWN BY COUNTRY, TECHNOLOGY, END USERS AND APPLICATION 61
9.2.1 GERMANY MARKET BREAKDOWN BY TYPE OF HUMAN INSULIN, BY TYPE OF TRADITIONAL HUMAN INSULIN, AND BY TYPE OF MODERN HUMAN INSULIN 66
9.2.2 THE U.K. MARKET BREAKDOWN BY TYPE OF HUMAN INSULIN, BY TYPE OF TRADITIONAL HUMAN INSULIN, AND BY TYPE OF MODERN HUMAN INSULIN 69
9.2.3 FRANCE MARKET BREAKDOWN BY TYPE OF HUMAN INSULIN, BY TYPE OF TRADITIONAL HUMAN INSULIN, AND BY TYPE OF MODERN HUMAN INSULIN 72
9.3 ASIA-PACIFIC MARKET BREAKDOWN BY COUNTRY, TECHNOLOGY, END USERS AND APPLICATION 76
9.3.1 JAPAN MARKET BREAKDOWN BY TYPE OF HUMAN INSULIN, BY TYPE OF TRADITIONAL HUMAN INSULIN, AND BY TYPE OF MODERN HUMAN INSULIN 80
9.3.2 CHINA MARKET BREAKDOWN BY TYPE OF HUMAN INSULIN, BY TYPE OF TRADITIONAL HUMAN INSULIN, AND BY TYPE OF MODERN HUMAN INSULIN 84
9.3.3 INDIA MARKET BREAKDOWN BY TYPE OF HUMAN INSULIN, BY TYPE OF TRADITIONAL HUMAN INSULIN, AND BY TYPE OF MODERN HUMAN INSULIN 87
9.4 REST OF THE WORLD (ROW) MARKET BREAKDOWN BY TYPE, BY TYPE OF TRADITIONAL HUMAN INSULIN AND BY TYPE OF MODERN HUMAN INSULIN 91
CHAPTER 10.COMPETITIVE ANALYSIS AND MARKET SHARE 95
10.1 PORTER’S FIVE FORCES OF COMPETITIVE POSITION ANALYSIS 95
10.1.1BARGAINING POWER OF BUYERS 95
10.1.2BARGAINING POWER OF SUPPLIERS 96
10.1.3THREAT OF NEW ENTRANTS 96
10.1.4INTENSITY OF RIVALRY 96
10.1.5THREAT OF SUBSTITUTES 97
10.2 COMPETITIVE POSITIONING OF KEY COMPETITORS AND MARKET ANALYSIS 97
CHAPTER 11.COMPANY PROFILES 99
11.1BIOCON LTD. 99
11.1.1BUSINESS OVERVIEW 99
11.1.2PRODUCTS AND SERVICES 99
11.1.3RECENT DEVELOPMENTS 100
11.1.4KEY P&L METRICS 100
11.2TONGHUA DONGBAO PHARMACEUTICALS CO., LTD. 100
11.2.1BUSINESS OVERVIEW 101
11.2.2PRODUCTS AND SERVICES OFFERINGS 101
11.2.3RECENT DEVELOPMENTS 101
11.2.4KEY P&L METRICS 101
11.3ADOCIA 102
11.3.1BUSINESS OVERVIEW 102
11.3.2PRODUCTS AND SERVICES 102
11.3.3RECENT DEVELOPMENTS 103
11.3.4KEY P&L METRICS 103
11.4MERCK & CO. 104
11.4.1BUSINESS OVERVIEW 104
11.4.2PRODUCTS AND SERVICES 104
11.4.3RECENT DEVELOPMENTS 105
11.4.4KEY P&L METRICS 105
11.5JULPHAR 105
11.5.1BUSINESS OVERVIEW 106
11.5.2PRODUCTS AND SERVICES 106
11.5.3RECENT DEVELOPMENTS 106
11.5.4KEY P&L METRICS 107
11.6PFIZER, INC. 107
11.6.1BUSINESS OVERVIEW 107
11.6.2PRODUCTS AND SERVICES 108
11.6.3RECENT DEVELOPMENTS 108
11.6.4KEY P&L METRICS 108
11.7BRISTOL-MYERS SQUIBB COMPANY 109
11.7.1BUSINESS OVERVIEW 109
11.7.2PRODUCTS AND SERVICES 109
11.7.3RECENT DEVELOPMENTS 110
11.7.4KEY P&L METRICS 110
11.8GLAXOSMITHKLINE PLC 110
11.8.1BUSINESS OVERVIEW 110
11.8.2PRODUCTS AND SERVICES 111
11.8.3RECENT DEVELOPMENTS 111
11.8.4KEY P&L METRICS 111
11.9ORAMED PHARMACEUTICALS, INC. 112
11.9.1BUSINESS OVERVIEW112
11.9.2PRODUCTS AND SERVICES 112
11.9.3RECENT DEVELOPMENTS 112
11.9.4KEY P&L METRICS 113
11.10NOVO NORDISK A/S 114
11.10.1BUSINESS OVERVIEW 114
11.10.2PRODUCTS AND SERVICES 114
11.10.3RECENT DEVELOPMENTS 114
11.10.4KEY P&L METRICS 115
11.11ELI LILLY AND COMPANY 116
11.11.1BUSINESS OVERVIEW 116
11.11.2PRODUCTS AND SERVICES 116
11.11.3RECENT DEVELOPMENTS 116
11.11.4KEY P&L METRICS 117
11.12SANOFI 118
11.12.1BUSINESS OVERVIEW 118
11.12.2PRODUCTS AND SERVICES 118
11.12.3RECENT DEVELOPMENTS 119
11.12.4KEY P&L METRICS 119

……Continued

 

MORE REPORTS FROM OUR DATABASE:

http://www.marketwatch.com/story/global-sterilized-packaging-market-statistics-cagr-outlook-and-covid-19-impact-2021-2026-2021-03-17

http://www.marketwatch.com/story/global-high-fiber-biscuits-market-size-share-value-and-competitive-landscape-2020-2026-2021-03-19

http://www.marketwatch.com/story/global-polycarbonate-diol-market-size-share-value-and-competitive-landscape-2024-2021-03-23

http://www.marketwatch.com/story/global-industrial-radiography-equipment-market-insights-overview-analysis-and-forecast-2021-2021-03-23

http://www.marketwatch.com/story/global-telecom-service-provider-investment-capex-analysis-industry-market-outlook-industry-analysis-and-prospect-2020-2021-03-30

         

 

CONTACT DETAILS :

sales@wiseguyreports.com

+44 203 500 2763

+1 62 825 80070        

971 0503084105